| Role |
Name |
Disclosure |
Details |
| Author | Gary K Arthur, MD, Clinical Assistant Professor, Department of Psychiatry and Behavioral Medicine, University of South Florida College of Medicine | Nothing to disclose | Details | | Coauthor | Kim Monnell, DO, Consulting Staff, Department of Neurology, Sarasota Memorial Hospital | Nothing to disclose | Details | | Medical Editor | Denis F Darko, MD, Director, Central Nervous System Clinical Research, Clinical Science, Green Hospital | Nothing to disclose | Details | | Pharmacy Editor | Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine | Nothing to disclose | Details | | Managing Editor | David Bienenfeld, MD, Vice-Chair, Program Director, Professor, Department of Psychiatry, Wright State University School of Medicine | Nothing to disclose | Details | | CME Editor | Harold H Harsch, MD, Program Director of Geropsychiatry, Department of Geriatrics/Gerontology, Associate Professor, Department of Psychiatry and Department of Medicine, Froedtert Hospital, Medical College of Wisconsin | lilly BMS Forest Labs AstraZeneca Pfizer Northstar Novartis | Details | | Chief Editor | Stephen Soreff, MD, President of Education Initiatives, Nottingham, NH; Faculty, Metropolitan College of Boston University, Boston, MA | Nothing to disclose | Details |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Kim Monnell, Coauthor |
The contributor discloses no conflict of interest. |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Denis F Darko, Medical Editor |
The contributor discloses no conflict of interest. |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| David Bienenfeld, Managing Editor |
The contributor discloses no conflict of interest. |
|